Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2019 Feb 15;29(4):631-637. doi: 10.1016/j.bmcl.2018.12.043. Epub 2018 Dec 19.

Identification of BR101549 as a lead candidate of non-TZD PPARγ agonist for the treatment of type 2 diabetes: Proof-of-concept evaluation and SAR.

Author information

1
Research Center, Boryung Pharmaceuticals Co. Ltd., Republic of Korea.
2
New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation (DGMIF), Republic of Korea.
3
Research Center, Boryung Pharmaceuticals Co. Ltd., Republic of Korea. Electronic address: rose1998@boryung.co.kr.

Abstract

The new class of PPARgamma non-TZD agonist originally derived from the backbone of anti-hypertensive Fimasartan, BR101549, was identified as a potential lead for anti-diabetic drug development. The X-ray crystallography of BR101549 with PPARgamma ligand binding domain (LBD) revealed unique binding characteristics versus traditional TZD full agonists. The lead candidate, BR101549, has been found activating PPARgamma to the level of Pioglitazone in vitro and indeed has demonstrated its effects on blood glucose control in mouse proof-of-concept evaluation. The attempts to improve its metabolic stability profile through follow-up SAR including deuterium incorporation have been also described.

KEYWORDS:

Antidiabetics; Drug discovery; PPARgamma agonist

PMID:
30594432
DOI:
10.1016/j.bmcl.2018.12.043

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center